Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)

Kyaw Zin Thein, Sarina A. Piha-Paul, Apostolia Tsimberidou, Daniel D. Karp, Filip Janku, Abdulrazzak Zarifa, Jatin Shah, Denái R. Milton, Stacie Bean, Lacey McQuinn, Jing Gong, Rivka Colen, Brett W. Carter, Vivek Subbiah, Deby C. Ogbonna, Shubham Pant, Funda Meric-Bernstam, Aung Naing

Research output: Contribution to journalComment/debatepeer-review

Abstract

The article Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study was originally published electronically on the publisher’s internet portal on 28 April 2021 without open access. After publication in volume [39], issue [5], pages [1357–1365] the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to

Original languageEnglish (US)
JournalInvestigational New Drugs
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study (Investigational New Drugs, (2021), 39, 5, (1357-1365), 10.1007/s10637-021-01119-0)'. Together they form a unique fingerprint.

Cite this